{"commentary":{"count":78,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":36,"podcast":21,"x_thread":20,"x_video":1},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03737643\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"DUO-O","nct_id":"NCT03737643","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=duo-o-nct03737643. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":"DUO-O","arms":[{"description":"Platinum-based chemotherapy in combination with bevacizumab and durvalumab placebo (saline IV infusion) followed by maintenance bevacizumab, durvalumab placebo (saline IV infusion) and olaparib placebo (tablets).","label":"Arm 1","type":"ACTIVE_COMPARATOR"},{"description":"Platinum-based chemotherapy in combination with bevacizumab and durvalumab followed by maintenance bevacizumab, durvalumab and olaparib placebo.","label":"Arm 2","type":"EXPERIMENTAL"},{"description":"Platinum-based chemotherapy in combination with bevacizumab and durvalumab followed by maintenance bevacizumab, durvalumab and olaparib.","label":"Arm 3","type":"EXPERIMENTAL"},{"description":"Platinum-based chemotherapy in combination with bevacizumab and durvalumab followed by maintenance bevacizumab, durvalumab and olaparib. Bevacizumab is optional according to local practice.","label":"tBRCAm cohort","type":"EXPERIMENTAL"}],"collaborators":["European Network of Gynaecological Oncological Trial Groups (ENGOT)","GOG Foundation","Myriad Genetic Laboratories, Inc."],"completion_date":{"date":"2026-12-23","type":"ESTIMATED"},"conditions":["Advanced Ovarian Cancer"],"enrollment":{"count":1407,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Bevacizumab","type":"DRUG"},{"name":"Durvalumab","type":"DRUG"},{"name":"Olaparib","type":"DRUG"},{"name":"Placebo olaparib","type":"DRUG"},{"name":"Durvalumab placebo","type":"DRUG"},{"name":"Carboplatin+Paclitaxel","type":"DRUG"}],"last_update":"2026-07-07","lead_sponsor":"AstraZeneca","official_title":"A Phase III Randomised, Double-Blind, Placebo-Controlled, Multicentre Study of Durvalumab in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib in Newly Diagnosed Advanced Ovarian Cancer Patients (DUO-O).","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2025-03-17","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression-free Survival (PFS) by Investigator Assessment Using Modified RECIST 1.1 - Full Analysis Set","timeFrame":"At baseline, within 3 weeks of last dose of chemotherapy, then every 12 weeks for 3 years and thereafter every 24 weeks. Assessed until primary analysis - (05DEC2022 for Global cohort, 17MAR2025 for China cohort) - upto 46 months"},{"measure":"Progression-free Survival (PFS) by Investigator Assessment Using Modified RECIST 1.1 - (Full Analysis Set, HRD Positive)","timeFrame":"At baseline, within 3 weeks of last dose of chemotherapy, then every 12 weeks for 3 years and thereafter every 24 weeks. Assessed until DCO1 - (05DEC2022 for Global cohort, 17MAR2025 for China cohort) - upto 46 months"}],"references":[{"citation":"Gaitskell K, Rogozinska E, Platt S, Chen Y, Abd El Aziz M, Tattersall A, Morrison J. Angiogenesis inhibitors for the treatment of epithelial ovarian cancer. Cochrane Database Syst Rev. 2023 Apr 18;4(4):CD007930. doi: 10.1002/14651858.CD007930.pub3.","pmid":"37185961","type":"DERIVED"}],"start_date":{"date":"2019-01-04","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients","url":"https://clinicaltrials.gov/study/NCT03737643"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/duo-o-nct03737643"}